HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.

Abstract
The present study was undertaken to investigate the role of the hypothalamic tripeptide L-prolyl-L-leucyl-glycinamide (PLG) and its conformationally constrained analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) in modulating agonist binding to human dopamine (DA) receptor subtypes using human neuroblastoma SH-SY5Y cells stably transfected with respective cDNAs. Both PLG and PAOPA enhanced agonist [3H]N-propylnorapomorphine (NPA) and [3H]quinpirole binding in a dose-dependent manner to the DA D2L,D2S, and D4 receptors. However, agonist binding to the D1 and D3 receptors and antagonist binding to the D2L receptors by PLG were not significantly affected. Scatchard analysis of [3H]NPA binding to membranes in the presence of PLG revealed a significant increase in affinity of the agonist binding sites for the D2L, D2S, and D4 receptors. Analysis of agonist/antagonist competition curves revealed that PLG and PAOPA increased the population and affinity of the high-affinity form of the D2L receptor and attenuated guanosine 5'-(beta,gamma-imido)-triphosphate-induced inhibition of high-affinity agonist binding sites for the DA D2L receptor. Furthermore, direct NPA binding with D2L cell membranes pretreated with suramin, a compound that can uncouple receptor/G protein complexes, and incubated with and without DA showed that both PLG and PAOPA had only increased agonist binding in membranes pretreated with both suramin and DA, suggesting that PLG requires the D2L receptor/G protein complex to increase agonist binding. These results suggest that PLG possibly modulates DA D2S, D2L, and D4 receptors in an allosteric manner and that the coupling of D2 receptors to the G protein is essential for this modulation to occur.
AuthorsVaneeta Verma, Amandeep Mann, Willard Costain, Giuseppe Pontoriero, Jessica M Castellano, Kevin Skoblenick, Suresh K Gupta, Zdenek Pristupa, Hyman B Niznik, Rodney L Johnson, Venugopalan D Nair, Ram K Mishra
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 315 Issue 3 Pg. 1228-36 (Dec 2005) ISSN: 0022-3565 [Print] United States
PMID16126839 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Dopamine Agonists
  • Peptides
  • Receptors, Dopamine
  • Suramin
  • MSH Release-Inhibiting Hormone
  • GTP-Binding Proteins
Topics
  • Binding, Competitive (drug effects)
  • Cell Line, Tumor
  • Dopamine Agonists (metabolism, pharmacology)
  • GTP-Binding Proteins (antagonists & inhibitors)
  • Humans
  • MSH Release-Inhibiting Hormone (pharmacology)
  • Models, Chemical
  • Molecular Structure
  • Neuroblastoma (metabolism, pathology)
  • Peptides (chemistry, pharmacology)
  • Receptors, Dopamine (classification, drug effects)
  • Suramin (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: